.png)
.png)
Stablepharma and BB-NCIPD Ltd (Bul Bio) to develop a fridge-free Tetanus mono vaccine.
Stablepharma Ltd. and BB-NCIPD Ltd. (Bul Bio) have signed a second agreement for the exclusive bulk supply and commercialization of the Tetanus vaccine (SPVX06), following a similar arrangement for the Tetanus diphtheria vaccine (SPVX02) last year.
Touchlight creates world’s largest DNA manufacturing facilities in London, UK
- Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Supplying many of the top biopharmaceutical companies in the world.
Madonna, mass consumption and microbes
In his guest blog, Dr Edward Green, CEO at NCIMB shares the potential of microbes to achieve some of the UN's Sustainable Development Goals and address global challenges.
LifeArc announces strategic partnership with PrecisionLife as part of its Motor Neuron Disease translational challenge
Partnership aims to develop and commercialise a portfolio of precision MND therapeutics supported by biomarkers for patients most likely to respond.
Prioritising patient access
Next-generation sequencing and many other tools provide tremendous new insights into human biology. Emerging techniques, such as CRISPR technology and cell and gene therapies are providing new opportunities to treat and possibly even cure some of the most intractable diseases.
Thinking outside the triangle is key to the UK becoming a science superpower
Discovery Park CEO Mayer Schreiber reflects on the need to navigate past the lab shortages that have been preventing companies from scaling.
Innovation in bioprocessing: How BioProduction by SEKISUI became a leader in global manufacturing
Louise Digby, Commercial Director at BioProduction by SEKISUI, shares challenges, accomplishments and hurdles faced by the company, from building a strong, committed team, to securing investment to expand their cGMP facility.
Partnership with BIA: the gate for future leaders of global biotech industry
The increased number of MSc graduates has led students to think about their return on investment and how they will stand out amongst the crowd. Embedding employability skills in the design of contemporary courses begins with employers’ needs and demands because they are the ultimate arbiters of employability.
NHS Centre for making products for revolutionary cell and gene therapies
Hollie Yaxley, Business Development Manager – Clinical Biotechnology Centre (CBC) and Teresina Pinnington, Head of Business Development, NHS Blood and Transplant (NHSBT) write about the new facility in Filton, Bristol which will support the UK's ambition to grow the cell and gene therapy industry.
Mergermarket interviews Stablepharma on future IPO and Series B raise to launch two fridge-free vaccines
Stablepharma, a UK developer of the world’s first fridge-free vaccines, is evaluating an IPO and a financing round to bring two vaccines to market, CEO Özgür Tuncer told Mergermarket.